Immunovant
Logotype for Immunovant Inc

Immunovant (IMVT) investor relations material

Immunovant Q2 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immunovant Inc
Q2 2027 earnings summary9 Nov, 2026

Executive summary

  • Development focus shifted fully to IMVT-1402 after batoclimab was discontinued in April 2026; no product revenue has been generated.

  • IMVT-1402 600 mg met the Week 28 primary endpoint in difficult-to-treat RA; $722.3M in cash was expected to fund the current plan through a potential Graves’ disease launch.

Financial highlights

  • Q2 operating expenses were $104.2M vs. $131.8M YoY; net loss was $97.2M vs. $126.5M, and loss per share was $0.47 vs. $0.73.

  • Q2 R&D was $85.0M vs. $114.2M YoY, reflecting batoclimab wind-down and manufacturing-cost timing; G&A rose to $19.1M from $17.5M, partly due to pre-commercial investment.

  • H1 operating expenses were $264.5M vs. $259.0M; net loss was $250.5M vs. $247.1M, and loss per share was $1.22 vs. $1.43.

  • H1 R&D was $227.6M vs. $215.4M, primarily reflecting IMVT-1402 trials and manufacturing; G&A was $36.8M vs. $43.5M.

  • Cash and cash equivalents were $722.3M at September 30, 2026, down from $902.1M at March 31; H1 operating cash use was $207.6M.

Outlook and guidance

  • Current cash was expected to fund the operating plan through potential IMVT-1402 launch in Graves’ disease; potential expansion after D2T RA results was not included, with updated runway guidance expected if plans are finalized.

  • Top-line results are expected in 2027 for Graves’ disease and myasthenia gravis, and in 2028 for CIDP.

  • FDA discussions on the D2T RA registrational path were planned for later in 2026; trial design and development plans remain subject to regulatory alignment.

  • Advancement in Sjögren’s beyond the ongoing, fully enrolled Phase 2 trial is considered unlikely.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Immunovant earnings date

Logotype for Immunovant Inc
Investor Day 20269 Dec, 2026
Immunovant
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Immunovant earnings date

Logotype for Immunovant Inc
Investor Day 20269 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for patients with autoimmune diseases. Leveraging advanced anti-FcRn technology, Immunovant aims to create targeted therapies designed to address the complex and variable nature of autoimmune conditions. The company's approach is centered on improving the lives of patients by developing treatments that can potentially modify or halt the autoimmune response without compromising the immune system's ability to fight infections. Immunovant's research pipeline includes promising investigational products that embody the company's commitment to advancing the field of immunology and providing new options for individuals affected by autoimmune diseases. The company is headquartered in New York, NY, and its shares are listed on the Nasdaq.